ロード中...
PARP inhibitors for Homologous Recombination- Deficient Prostate Cancer
INTRODUCTION: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant di...
保存先:
| 出版年: | Expert Opin Emerg Drugs |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088797/ https://ncbi.nlm.nih.gov/pubmed/29595348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2018.1459563 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|